The development of Type 1 Diabetes (T1D) relies on complex interrelationships between cells of the immune system [e.g., DC, CD8+ T cells] and genes imparting susceptibility or resistance to the disease that underlie the autoimmune destruction of insulin producing pancreatic ? cells. While a broad body of evidence certainly exists to support this notion (and we ourselves believe it true), the exact mechanism by which autoimmune ? cell destruction is facilitated remains unclear. In addition, the relative contributions of each facet (i.e., cells, genes) play in the process remain, to a large extent, unknown. Mechanistic studies of T1D-associated susceptibility alleles are complicated by polygenic inheritance such that no two individuals are truly alike. Hence, studies are severely hampered by a lack of power in populations, and the inability to isolate the functional impact of a variant to a specific cell type. Here we present a solution that focuses on individual alleles usin an innovative isogenic mode that takes advantage of cutting edge technologies. We have created an experimental platform to study how specific genetic risk variants precipitate immune dysregulation leading to cytotoxic CD8+ T lymphocyte (CTL) activation and ? cell destruction. We hypothesize that genetically regulated defects in PTPN22 promote;i) immunogenic DC, ii) TH1 responses, iii) pancreatic vascular inflammation and CTL homing, and iv) pathogenic CTL activity towards ? cells coupled with reduced activation induced CTL death: each of these tenants form an aim of this grant. Further, we posit that defects reach full potential when immune cells and endothelial cells are excessively sensitive to activation by endogenous or exogenous factors that stimulate inflammation, thus linking environment and immunogenetics in T1D. Here we will utilize a novel experimental pipeline where PTPN22R (T1D resistant), PTPN22W (T1D susceptible) or PTPN22 deletion (PTPN22-/-) alleles are carried by isogenic human immune and endothelial cells engineered from induced pluripotent stem cells [iPSC]. The iPSC system allows exquisite control of T1D disease alleles, where the susceptible allele can be replaced by the resistant allele (and vice versa) providing a constant genetic background upon which effects of a single risk allotype can be studied without complicating epistatic effects, in a manner analogous to studies in genetically modified mice. This system proposed here will provide an unprecedented capacity to interrogate molecular and cellular interactions under isogenic conditions to provide mechanistic understanding of how PTPN22 alleles regulate individual steps of T1D pathogenesis and how those steps interrelate to bring upon T1D onset. Importantly, this study will also lay the groundwork for future investigations of single or multipl T1D susceptibility genes using this innovative strategy.
Our goal is to create an innovative platform to study how Type 1 Diabetes genetic risk factors precipitate autoimmunity leading to the loss of insulin producing cells. This system will provide an unprecedented capacity to interrogate molecular and cellular interactions under isogenic conditions to provide a vastly improved mechanistic understanding of how risk alleles regulate individual steps of Type 1 Diabetes pathogenesis and how those steps interrelate to bring upon Type 1 Diabetes onset.
|Perry, Daniel J; Wasserfall, Clive H; Oram, Richard A et al. (2018) Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling. Sci Rep 8:4529|
|Chen, Yi-Guang; Mathews, Clayton E; Driver, John P (2018) The Role of NOD Mice in Type 1 Diabetes Research: Lessons from the Past and Recommendations for the Future. Front Endocrinol (Lausanne) 9:51|
|Amatya, Christina; Radichev, Ilian A; Ellefson, Jacob et al. (2018) Self-Transducible Bimodal PDX1-FOXP3 Protein Lifts Insulin Secretion and Curbs Autoimmunity, Boosting Tregs in Type 1 Diabetic Mice. Mol Ther 26:184-198|
|Relling, M V; Krauss, R M; Roden, D M et al. (2017) New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine. Clin Pharmacol Ther 102:897-902|
|Driver, John P; Racine, Jeremy J; Ye, Cheng et al. (2017) Interferon-? Limits Diabetogenic CD8+ T-Cell Effector Responses in Type 1 Diabetes. Diabetes 66:710-721|
|Michels, Aaron W; Landry, Laurie G; McDaniel, Kristen A et al. (2017) Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes. Diabetes 66:722-734|
|Rogers, Geoffrey L; Shirley, Jamie L; Zolotukhin, Irene et al. (2017) Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells. Blood 129:3184-3195|
|Newby, Brittney N; Mathews, Clayton E (2017) Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front Endocrinol (Lausanne) 8:232|
|Newby, Brittney N; Brusko, Todd M; Zou, Baiming et al. (2017) Type 1 Interferons Potentiate Human CD8+ T-Cell Cytotoxicity Through a STAT4- and Granzyme B-Dependent Pathway. Diabetes 66:3061-3071|
|Whitener, Robert L; Gallo Knight, Lisa; Li, Jianwei et al. (2017) The Type 1 Diabetes-Resistance Locus Idd22 Controls Trafficking of Autoreactive CTLs into the Pancreatic Islets of NOD Mice. J Immunol 199:3991-4000|
Showing the most recent 10 out of 30 publications